Classical strategies involving the use of immunomodulatory drugs (IMIDs) such as lenalidomide or novel approaches comprising next-generation class of IRF4 antisense oligonucleotides (ASOs), that employ constrained ethyl residues that mediate RNase H-dependent degradation of IRF4 mRNA, mediate IRF4 down-modulation, interfering with the IRF4-regulated transcriptional program and IRF4-MYC feedback loop in MM. The gene discussed is MYC; the disease is Miyoshi myopathy.